Inhibition of Factor Xa
- First Online:
Anticoagulant therapy plays an important role in the prevention and treatment of pathologic arterial and venous thrombosis. There is increasing enthusiasm in the inhibition of Factor Xa as a target to achieve therapeutic anticoagulation because of its central and ‘upstream’ position in the coagulation process.
The indirect, selective, parenteral Factor Xa inhibitor fondaparinux sodium (synthetic pentasaccharide) has been studied extensively in the prevention and treatment of venous thromboembolism. In an overview of four studies in patients undergoing major orthopedic surgery, fondaparinux sodium was associated with a 55% reduction in recurrent thromboembolism, albeit with a modest increase in bleeding. Preliminary results from phase II studies of fondaparinux sodium in patients with ST-elevation and non-ST-elevation acute coronary syndromes have been promising and have led to the initiation of two large phase III trials, which are currently underway. Idraparinux sodium, a long-acting synthetic pentasaccharide, is currently being investigated as a once-weekly alternative to other long-term anticoagulants.
DX-9065a and razaxaban are two of many direct selective Factor Xa inhibitors currently in development. DX-9065a has been studied in phase II trials in patients undergoing percutaneous coronary intervention and in those with non-ST-elevation acute coronary syndromes. Razaxaban has been studied in a phase II trial in patients who have undergone orthopedic surgery. Data from these trials, although preliminary and based on small numbers of patients, suggest that direct selective Factor Xa inhibition may provide effective anticoagulation, perhaps without excessive bleeding.
Inhibition of Factor Xa is a promising target for the prevention and treatment of thrombosis in both the venous and arterial circulation. Ongoing investigation with numerous oral and parenteral inhibitors of Factor Xa will establish the potential of Factor Xa as a target for therapeutic anticoagulation.
- 13.Becker RC. The evolution of Factor Xa antagonists in cardiovascular disease. Daiichi Symposium. XIX Congress of the International Society of Thrombosis and Hemostasis; 2003 Jul 15; Birmingham, UK.Google Scholar
- 19.GlaxoSmithKline, Research Triangle Park, NC, USA. Arixtra® (fondaparinux sodium) prescribing information, May 2005 [online]. Available from URL: http://us.gsk.com [Accessed 2005 Jul 4].
- 21.Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. The PENTATHALON 2000 Study Steering Committee. Lancet 2002; 359: 1721–6.PubMedCrossRefGoogle Scholar
- 22.Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. The European PentasaccHaride Elective SUrgery Study (EPHESUS) Steering Committee. Lancet 2002; 359: 1715–20.PubMedCrossRefGoogle Scholar
- 26.Center for Drug Evaluation and Research. Final printed labelling: Arixtra™ injection [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2001/21-345_Arixtra_prntlbl.pdf [Accessed 2005 Jun 20].
- 28.Agnelli G, Bergqvist D, Cohen A, et al. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study. J Thromb Haemost 2003; 1 Suppl. 1 July: OC396.Google Scholar
- 34.The MICHELANGELO studies: OASIS 5 (UA/NSTEMI) [online]. Available from URL: http://www.phri.ca/oasis5/index.htm [Accessed 2005 Jul 4].
- 49.Alexander JH, Becker RC, Hasselblad V, et al. Effect of the direct Factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease. J Thromb Haemost 2003; 1 Suppl. 1 July: P2017.Google Scholar
- 55.Lassen MR, Davidson BL, Gallus A, et al. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery: on behalf of the Razaxaban investigators [abstract]. Blood 2003; 102(11): 41.Google Scholar